title: Pattern of metastasis and outcome in patients with breast cancer.
abstract: There is growing evidence about differences in metastatic spread among breast cancer (BC) biologic subtypes (BS). Aim of this study was to analyze the pattern of metastasization according to BS and to explore the corresponding prognosis. A series of 544 consecutive patients receiving anticancer therapy for metastatic BC from 2004 to 2013, was analyzed. BS were defined by immunohistochemistry according to St Gallen 2013 criteria. Association between BS and the different distant localizations was analyzed. Prognosis was described in terms of overall survival (OS), progression free survival (PFS) and post progression survival (PPS). Results were reported taking luminal A BC as reference. Triple negative BC showed a higher tropism for lung (OR 4.30 95% CI 1.41-13.1), while non luminal HER2 subtype was associated with a higher rate of liver metastases (OR 3.61 95% CI 1.36-9.58). All subtypes were associated with a lower risk of bone-only localization. Central nervous system (CNS) involvement was more common in HER2 positive BC (OR 6.3, 95% CI 1.08-36.66). Liver, lung and CNS involvement influenced negatively OS (HR 1.64, 95% CI 1.29-2.07; HR 1.49, 95% CI 1.18-1.90; HR 2.891, 95% CI 1.85-4.51, respectively) and PFS (HR 1.39, 95% CI 1.13-1.71; HR 1.26, 95% CI 1.02-1.55; HR 1.75, 95% CI 1.12-2.71, respectively). Multivariate analysis confirmed liver involvement as independent predictor of worse OS (HR 1.64, 95% CI 1.15-2.34). Stratification by metastatic pattern showed significant differences in terms of PPS but not in terms of PFS. The study suggests that BS may be characterized by typical patterns of metastatic spread and have different impact on clinical outcome.
authors: Department of Oncology, University Hospital of Udine, Piazzale S.M. Misericordia, 33100, Udine, Italy.
authors: L
authors: L
authors: Gerratana
authors: V
authors: V
authors: Fanotto
authors: M
authors: M
authors: Bonotto
authors: S
authors: S
authors: Bolzonello
authors: A M
authors: AM
authors: Minisini
authors: G
authors: G
authors: Fasola
authors: F
authors: F
authors: Puglisi
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D016543:Central Nervous System Neoplasms / Q000556:secondary; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000556:secondary; D015999:Multivariate Analysis; D009362:Neoplasm Metastasis; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012044:Regression Analysis; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
references: Crit Rev Oncol Hematol. 2013 Jul;87(1):69-79
references: 23369750
references: Breast Cancer Res. 2011 Sep 13;13(5):R87
references: 21914172
references: Cancer Chemother Pharmacol. 2010 Aug;66(3):507-16
references: 19956951
references: J Clin Oncol. 2013 Jan 10;31(2):203-9
references: 23233704
references: Crit Rev Oncol Hematol. 2014 Aug;91(2):130-41
references: 24726438
references: J Intern Med. 2013 Aug;274(2):113-26
references: 23844915
references: Crit Rev Oncol Hematol. 2011 Dec;80(3):433-49
references: 21330148
references: Clin Breast Cancer. 2013 Apr;13(2):88-94
references: 23218473
references: Ann Oncol. 2013 Sep;24(9):2206-23
references: 23917950
references: Oncologist. 2014 Jun;19(6):608-15
references: 24794159
references: Breast. 2012 Feb;21(1):50-7
references: 21865043
references: J Clin Oncol. 2010 Jul 10;28(20):3271-7
references: 20498394
references: Clin Exp Metastasis. 2013 Dec;30(8):951-6
references: 23775210
references: Cancer Treat Rev. 2014 Feb;40(1):129-38
references: 23891266
references: Eur J Cancer. 2009 Nov;45(16):2792-8
references: 19643597
references: J Clin Oncol. 2013 Sep 1;31(25):3083-90
references: 23897954
references: Ann Oncol. 2010 Nov;21(11):2169-74
references: 20427349
references: Breast Cancer Res Treat. 2014 Jun;145(3):725-34
references: 24706168
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855